Prospects for Treatment of Latent HIV

被引:77
作者
Barton, K. M. [1 ]
Burch, B. D. [2 ]
Soriano-Sarabia, N. [2 ]
Margolis, D. M. [1 ,2 ,3 ]
机构
[1] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[3] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA
关键词
T-CELLS; DEACETYLASE INHIBITORS; GENE-EXPRESSION; PD-1; BLOCKADE; IN-VIVO; ACTIVATION; RESISTANCE; INFECTION; DISEASE; CXCR4;
D O I
10.1038/clpt.2012.202
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent advances in antiretroviral therapy (ART) have drastically improved the quality of life for people with HIV infection. However, owing to the persistence of latent HIV in the presence of therapy, patients must remain on therapy indefinitely. Currently, the solution to the HIV pandemic rests on the prevention of new infections and many decades of ART for the steadily expanding number of people infected worldwide. ART is costly, requires ongoing medical care, and can have side effects, thereby preventing its universal availability. Therefore, to escape the ironic burdens of therapy, efforts have begun to develop treatments for latent HIV infection. Current approaches propose either complete eradication of infection or induction of a state of stringent control over viral replication without ART. This review will discuss these strategies in detail and their potential for clinical development.
引用
收藏
页码:46 / 56
页数:11
相关论文
共 75 条
[1]   Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation [J].
Allers, Kristina ;
Huetter, Gero ;
Hofmann, Joerg ;
Loddenkemper, Christoph ;
Rieger, Kathrin ;
Thiel, Eckhard ;
Schneider, Thomas .
BLOOD, 2011, 117 (10) :2791-2799
[2]   CXCR4 and CCR5 shRNA transgenic CD34+cell derived macrophages are functionally normal and resist HIV-1 infection [J].
Anderson, J ;
Akkina, R .
RETROVIROLOGY, 2005, 2 (1)
[3]  
ANDREEFF M, 1992, BLOOD, V80, P2604
[4]  
[Anonymous], 19 C RETR OPP INF SE
[5]  
[Anonymous], 2011, Progress report 2011: Global HIV/AIDS response
[6]   Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy [J].
Archin, N. M. ;
Liberty, A. L. ;
Kashuba, A. D. ;
Choudhary, S. K. ;
Kuruc, J. D. ;
Crooks, A. M. ;
Parker, D. C. ;
Anderson, E. M. ;
Kearney, M. F. ;
Strain, M. C. ;
Richman, D. D. ;
Hudgens, M. G. ;
Bosch, R. J. ;
Coffin, J. M. ;
Eron, J. J. ;
Hazuda, D. J. ;
Margolis, D. M. .
NATURE, 2012, 487 (7408) :482-U1650
[7]   Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid [J].
Archin, Nancie M. ;
Espeseth, Amy ;
Parker, Daniel ;
Cheema, Manzoor ;
Hazuda, Daria ;
Margolis, David M. .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2009, 25 (02) :207-212
[8]   Restoring function in exhausted CD8 T cells during chronic viral infection [J].
Barber, DL ;
Wherry, EJ ;
Masopust, D ;
Zhu, BG ;
Allison, JP ;
Sharpe, AH ;
Freeman, GJ ;
Ahmed, R .
NATURE, 2006, 439 (7077) :682-687
[9]   Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].
Berger, Raanan ;
Rotem-Yehudar, Rinat ;
Slama, Gideon ;
Landes, Shimon ;
Kneller, Abraham ;
Leiba, Merav ;
Koren-Michowitz, Maya ;
Shimoni, Avichai ;
Nagler, Arnon .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051
[10]   DISTINCT MODULATORY EFFECTS OF BRYOSTATIN-1 AND STAUROSPORINE ON THE BIOSYNTHESIS AND EXPRESSION OF THE HIV RECEPTOR PROTEIN (CD4) BY T-CELLS [J].
BOTO, WMO ;
BROWN, L ;
CHREST, J ;
ADLER, WH .
CELL REGULATION, 1991, 2 (02) :95-103